Lim Cynthia Ciwei, Ang Andrew Teck Wee, Kadir Hanis Bte Abdul, Lee Puay Hoon, Goh Bandy Qiuling, Harikrishnan Sudha, Kwek Jia Liang, Gan Sheryl S W, Choo Jason Chon Jun, Tan Ngiap Chuan
Department of Renal Medicine, Singapore General Hospital, Academia Level 3, 20 College Road, Singapore, 169856, Singapore.
SingHealth Polyclinic, Singapore, Singapore.
Drugs Aging. 2021 Feb;38(2):147-156. doi: 10.1007/s40266-020-00824-4. Epub 2020 Nov 30.
Prolonged systemic non-steroidal anti-inflammatory drugs (NSAIDs) have been associated with adverse renal outcomes among older adults. However, there is scant data regarding the renal safety of topical and short-course systemic NSAIDs. We aimed to evaluate the risk of acute adverse renal outcomes among older adults prescribed topical and short-term systemic NSAIDs.
We conducted a retrospective cohort study of all older adults, age 60 years and above, who received prescriptions between July 2015 and December 2017 from the largest tertiary hospital and a major public primary care institution in Singapore. Data from 6 months before until 30 days after the first prescription were retrieved from electronic medical records. The primary outcome was the incidence of acute kidney injury (serum creatinine increased >26.5 µmol/L or >50% from baseline) and/or hyperkalemia within 30 days. A multi-variate analysis taking into account age, sex, co-morbidities, baseline-estimated glomerular filtration rate and serum potassium, NSAID route of administration, and concurrent renin-angiotensin-aldosterone system blocker and diuretic prescription was performed to evaluate factors associated with the primary outcome.
We identified 12,773 older adults with incident prescriptions: 3982 (31.2%) received short-course systemic NSAIDs, 3784 (29.6%) received topical NSAIDs, and 5007 (39.2%) did not receive any NSAID. Both short-course systemic NSAIDs (adjusted odds ratio [OR] 1.59, 95% confidence interval [CI] 1.41-1.80, p < 0.001) and topical NSAIDs (adjusted OR 1.48, 95% CI 1.31-1.67, p < 0.001), compared with the no-NSAID group, were independently associated with the primary outcome. Among older adults with co-morbid conditions and prescribed NSAIDs, topical NSAIDs had a reduced odds of 30-day incident acute kidney injury and/or hyperkalemia in diabetes mellitus (adjusted OR 0.78, 95% CI 0.65-1.06, p = 0.007), chronic kidney disease (adjusted OR 0.74, 95% CI 0.60-0.90, p = 0.003), and cardiovascular disease (adjusted OR 0.54, 95% CI 0.37-0.79, p < 0.001), compared with short-course systemic NSAIDs.
NSAIDs increased the risk of acute adverse renal events. Topical NSAIDs, compared with short-course systemic NSAIDs, were associated with a reduced incidence of acute kidney injury and/or hyperkalemia among older adults with additional risk factors.
长期使用全身性非甾体抗炎药(NSAIDs)与老年人不良肾脏结局相关。然而,关于局部用和短期全身性NSAIDs肾脏安全性的数据很少。我们旨在评估开具局部用和短期全身性NSAIDs处方的老年人发生急性不良肾脏结局的风险。
我们对2015年7月至2017年12月期间在新加坡最大的三级医院和一家主要的公立基层医疗机构就诊的所有60岁及以上老年人进行了一项回顾性队列研究。从电子病历中检索首次处方前6个月至处方后30天的数据。主要结局是30天内急性肾损伤(血清肌酐较基线水平升高>26.5µmol/L或>50%)和/或高钾血症的发生率。进行多变量分析,考虑年龄、性别、合并症、基线估计肾小球滤过率和血清钾、NSAIDs给药途径以及同时使用的肾素-血管紧张素-醛固酮系统阻滞剂和利尿剂处方,以评估与主要结局相关的因素。
我们确定了12773例有新处方的老年人:3982例(31.2%)接受短期全身性NSAIDs,3784例(29.6%)接受局部用NSAIDs,5007例(39.2%)未接受任何NSAIDs。与未使用NSAIDs组相比,短期全身性NSAIDs(调整后的优势比[OR]为1.59,95%置信区间[CI]为1.41-1.80,p<0.001)和局部用NSAIDs(调整后的OR为1.48,95%CI为1.31-1.67,p<0.001)均与主要结局独立相关。在有合并症且开具了NSAIDs处方的老年人中,与短期全身性NSAIDs相比,局部用NSAIDs在糖尿病(调整后的OR为0.78,95%CI为0.65-1.06,p=0.007)、慢性肾脏病(调整后的OR为0.74,95%CI为0.60-0.90,p=0.003)和心血管疾病(调整后的OR为0.54,95%CI为0.37-0.79,p<0.001)患者中,30天内发生急性肾损伤和/或高钾血症的几率降低。
NSAIDs增加了急性不良肾脏事件的风险。与短期全身性NSAIDs相比,局部用NSAIDs与有额外危险因素的老年人急性肾损伤和/或高钾血症的发生率降低相关。